An open-label, multi-centre study to evaluate efficacy and safety of gefitinib as the first-line treatment for locally advanced (IIIB), metastatic (IV) or recurrent pulmonary adenocarcinoma patients with EGFR [epidermal growth factor receptor] mutation

Trial Profile

An open-label, multi-centre study to evaluate efficacy and safety of gefitinib as the first-line treatment for locally advanced (IIIB), metastatic (IV) or recurrent pulmonary adenocarcinoma patients with EGFR [epidermal growth factor receptor] mutation

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2010

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Jun 2010 Actual patient number (46) added as reported by ClinicalTrials.gov.
    • 05 Oct 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 18 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top